sofadil

Sofadil (ST-007) is a small molecule neuroprotective agent developed by Beijing Scitech-Mq Pharmaceuticals for the treatment of acute ischemic stroke. It features a dual mechanism of action, functioning as a moderate, NR2B-selective N-methyl-D-aspartate (NMDA) receptor antagonist and a potent cellular osmotic antioxidant. By targeting both glutamate-induced excitotoxicity and free radical-mediated oxidative stress, Sofadil aims to provide a broader therapeutic window for neuroprotection compared to traditional NMDA antagonists. The drug has completed Phase I and Phase II clinical evaluations, demonstrating a favorable safety profile and potential efficacy in reducing neuronal damage following ischemic events.

Other names

Sophadil